Selected Publications
Thavaneswaran S, Rath E, Tucker K, Joshua AM, Hess D, Pinese M, Ballinger ML, Thomas DM. Therapeutic implications of germline genetic findings in cancer. Nat Rev Clin Oncol. 2019 Jun;16(6):386-396. doi: 10.1038/s41571-019-0179-3. Review.
Thavaneswaran S, Sebastian L, Ballinger ML, Best M, Hess D, Lee C, Sjoquist K, Hague W, Butow P, Simes J, Thomas DM. 2018 The Cancer Molecular Screening and Therapeutics Program (MoST) - A master protocol for multiple, parallel, signal-seeking clinical sub-studies. Med J Aust, 209:354-355.
Ballinger ML, Ferris NJ, Moodie K, Mitchell G, Shanley S, James PA*, Thomas DM*. Surveillance in germline TP53 mutation carriers utilizing whole body magnetic resonance imaging. JAMA Oncology, 2017 Dec 1;3(12):1735-1736.
Ballinger ML*, Best A*, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak R, Balieiro da Costa A, Santiago KM, Garber J, O'Neill A, Eeles RA, Evans G, Bleiker E, Sonke GS, Ruijs M, Loo C, Schiffman J, Naumer A, Kohlmann W, Strong LC, Bojadzieva J, Malkin D, Rednam SP, Stoffel EM, Koeppe E, Weitzel JN, Slavin TP, Nehoray B, Robson M, Walsh M, Manelli L, Villani A, Thomas DM*, Savage SA*. Baseline surveillance in Li-Fraumeni Syndrome using whole body magnetic resonance imaging: A Meta-Analysis. JAMA Oncology, 2017 Dec 1;3(12):1634-1639.
Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn S-M, Ahn J-H, Kim JE, Shanley S, Beshay V, Lor Randall R, Judson I, Seddon B, Campbell IG, Young M-A, Sarin R, Blay J-Y, O'Donoghue SI, Thomas DM for the International Sarcoma Kindred Study. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol 2016; 17:1261-1271.
Garsed, D.W., Marshall, O.J., Hsu, A., Young, S., Li, J., Corbin, V.D., Lansdell, B., Feng, Z.-P., Ito, M., Holloway, A.J., Copin, A., Pedeutour, F., Choo, K.H.A., Lisztwan, J., Papenfuss, A.T., Thomas, D.M. 2014 A single-nucleotide resolution map of a cancer-associated neochromosome. Cancer Cell, 26:653-667.
Kansara, M., Teng, M., Smyth, M.J., Thomas, D.M. 2014 Translational biology of osteosarcoma. Nature Reviews Cancer, 14:722-735.
Kansara, M., Leong, H.S., Lin, D.M., Popkiss, S., Pang, T., Garsed, D., Walkley, C., Cullinane, C., Ellul, J., Hicks, R., Haynes, N., Kuijjer, M., Cleton-Jansen, A.M., Hinds, P.W., Smyth, M.J., Thomas, D.M. 2013 An Rb-dependent, Il-6-mediated tumor suppressor pathway in radiation-induced osteosarcoma. Journal of Clinical Investigation, 123:5351-60.
Thomas, D.M., Albritton, K., Ferrari, A. 2010 Adolescent and young adult oncology: an emerging field. Journal of Clinical Oncology, 28:4781-2.
Thomas, D.M., Henshaw, R., Skubitz, K., Chawla, S., Staddon, A., Roudier, M., Smith, J., Ye, Z., Sohn, W., Dansey, R., Jun, S. 2010 Denosumab in subjects with giant cell tumor of bone: results from a phase 2 study. Lancet Oncology, 11:275-80.
Kansara, M., Tsang, M., Kodjabachian, L., Sims, N.A., Trivett, M.K., Ehrich, M., Dobrovic, A., Slavin, J.S., Choong, P.F.M., Simmons, P.J., Dawid, I.B., Thomas, D.M. 2009 Wnt Inhibitory Factor 1 is epigenetically silenced in human osteosarcoma, and acts as a tumor suppressor in vivo. Journal of Clinical Investigation, 119(4): 837-851.
Thomas, D.M., Carty, S.A., Piscopo, D.M., Lee, J-S., Wang, W-F., Forrester, W.C., Hinds, P.W. 2001 The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Molecular Cell, 8: 303-316.
More Garvan Publications
